SAN ANTONIO—A new analysis from UT Health San Antonio reports a striking, non-linear relationship between how long people sleep and levels of a blood biomarker tied to Alzheimer’s disease. The findings connect longer nightly sleep with increased concentrations of phosphorylated tau at threonine 181 (p-tau181), a modified tau protein that reflects neurodegenerative processes.
The study draws on data from 2,410 participants in the Framingham Heart Study, a long-running community cohort. Researchers modeled sleep duration alongside blood p-tau181 measurements while adjusting for multiple health and demographic factors, aiming to isolate the association from confounders.
Rather than producing a simple “more sleep equals more biomarker” pattern, the results show a curve. Sleep durations beginning around 8.5 to 9 hours were associated with higher p-tau181 levels, with the steepest rise occurring beyond 10 hours per night. This suggests that very long sleep may be a behavioral marker of early disease-related changes.
Lead author Vanessa M. Young cautions that the work is observational and captures a single point in time. That means the study cannot prove that longer sleep causes Alzheimer’s. Still, the authors argue that sleep patterns could be clinically useful for flagging individuals who may benefit from closer cognitive and biomarker monitoring.
To uncover the relationship, the team used flexible non-linear statistical approaches rather than forcing a straight-line assumption. Specifically, restricted cubic splines were applied to estimate how the sleep–biomarker link evolves across the range of sleep durations.
Importantly, the researchers tested whether similar patterns appeared for other Alzheimer- and neurodegeneration-related blood proteins. The sleep association disappeared for these markers once kidney function was considered, leaving p-tau181 as the main signal that remained robust after adjustment.
Young and colleagues interpret this specificity as potentially pointing toward Alzheimer-related biology rather than a broad effect of physiology on protein clearance. However, they emphasize that replication and prospective validation are needed before any clinical conclusions can be drawn.
The study appears amid a growing debate about whether sleep that is too short or too long harms brain health. Earlier work from the same research ecosystem suggested that sleeping nine hours or more could coincide with worse cognitive performance, especially in people with depression.
While the research does not prescribe sleep duration changes, it adds to a viral-ready narrative: sleep is not only about rest—it may also mirror underlying molecular changes. For clinicians and the public, the takeaway is a conversation starter—especially for those regularly sleeping 9 to 10 hours or more.
Subject of Research: Alzheimer’s disease; sleep duration; blood biomarkers (p-tau181)
Article Title: Non-linear associations between sleep duration and plasma p-tau181 in the Framingham Heart Study
News Publication Date: 16-July-2026 (article text); study published 19-May-2026
Web References: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71499
References: 10.1002/alz.71499
Image Credits: Not provided in the provided content
Keywords: Alzheimer’s disease, sleep duration, p-tau181, phosphorylated tau, non-linear modeling, biomarkers, restricted cubic splines, Framingham Heart Study, neurodegeneration
